Novartis (NVS) Scheduled to Post Quarterly Earnings on Tuesday

Novartis (NYSE:NVS) is scheduled to be issuing its quarterly earnings data before the market opens on Tuesday, October 29th. Analysts expect the company to announce earnings of $1.91 per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Novartis Stock Performance

Shares of NVS opened at $113.79 on Monday. Novartis has a 12 month low of $92.19 and a 12 month high of $120.92. The business’s fifty day simple moving average is $116.42 and its two-hundred day simple moving average is $108.64. The company has a market cap of $232.59 billion, a price-to-earnings ratio of 15.36, a P/E/G ratio of 1.66 and a beta of 0.57. The company has a current ratio of 0.93, a quick ratio of 0.72 and a debt-to-equity ratio of 0.47.

Analyst Upgrades and Downgrades

NVS has been the subject of several recent research reports. The Goldman Sachs Group restated a “neutral” rating and set a $121.00 target price (up from $119.00) on shares of Novartis in a research report on Thursday, September 5th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Novartis in a research report on Friday, July 19th. Jefferies Financial Group downgraded Novartis from a “buy” rating to a “hold” rating in a research report on Tuesday, September 3rd. Finally, Bank of America cut shares of Novartis from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $135.00 to $130.00 in a research note on Wednesday, September 11th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $120.70.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.